SCHEMBL715465

SCHEMBL715465

O=C(NC(O)C(=O)O)c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A2 P43004 1/20 0.56
HDAC3 O15379 1/20 0.52
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
IDO1 P14902 1/20 0.52
ALOX15 P16050 1/20 0.52
HDAC1 Q13547 1/20 0.52
CA9 Q16790 1/20 0.52
HDAC7 Q8WUI4 1/20 0.52
HDAC2 Q92769 1/20 0.52
HSD17B10 Q99714 1/20 0.52
HDAC8 Q9BY41 1/20 0.52
HDAC6 Q9UBN7 1/20 0.52
NCOR2 Q9Y618 1/20 0.52
LMNA P02545 2/20 0.52
HPGD P15428 2/20 0.52
CTRB1 P17538 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.49
ALDH1A1 P00352 2/20 0.49
MAPT P10636 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28118956 0.91 HDAC3 (0.56) SLC1A2HDAC3CA12CA1IDO1
SCHEMBL10350085 0.85 MAPT (0.56) SLC1A2HDAC3CA12CA1IDO1
SCHEMBL12561786 0.83 ALDH1A1 (0.49) SLC1A2HDAC3CA12CA1IDO1
SCHEMBL6673154 0.81 KDM4E (0.58) CA12CA1CA9LMNAALDH1A1
SCHEMBL10502948 0.80 GAA (0.58) SLC1A2HDAC3CA12CA1IDO1
SCHEMBL13038289 0.80 ALDH1A1 (0.50) SLC1A2HDAC3CA12CA1IDO1
SCHEMBL5908060 0.80 SLC1A2 (0.75) SLC1A2HDAC3CA12CA1IDO1
SCHEMBL5708283 0.80 SLC1A2 (0.58) SLC1A2HDAC3CA12CA1IDO1
SCHEMBL28641833 0.79 HDAC3 (0.58) SLC1A2HDAC3CA12CA1IDO1
SCHEMBL12050073 0.79 LMNA (0.49) SLC1A2HDAC3CA12CA1IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116396745-B Method for dispersing up-conversion luminescence nano particles in medium-polarity solvent and preparation method of film material 浙江大学 2025-05-06 CN claimed
WO-2024047073-A1 TOXIN-BINDER FOR HEMODIALYSIS UNIVERSITÄT HAMBURG (DE) 2024-03-07 WO claimed
CN-116660543-A Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof 中国人民解放军陆军军医大学第一附属医院 2023-08-29 CN claimed
CN-116396745-A Method for dispersing up-conversion luminescence nano particles in medium-polarity solvent and preparation method of film material 浙江大学 2023-07-07 CN claimed
EP-3973997-A1 MEMBRANE ACTIVE MOLECULES Branequest, Inc. (US) 2022-03-30 EP claimed
US-20200375958-A1 MEMBRANE ACTIVE MOLECULES KNOWLEDGE PHARMACEUTICALS INC. 2020-12-03 US claimed
EP-3615084-A1 MEMBRANE ACTIVE MOLECULES Branequest, Inc. (US) 2020-03-04 EP claimed
CN-109298115-A A variety of metabolin quantitative detecting methods and metabolism chip in biological sample 深圳市绘云生物科技有限公司 2019-02-01 CN claimed
CN-109107541-A The blood compatibility adsorbent of the dialysis of uremic toxins for protein combination B·布莱恩·阿维图姆股份公司 2019-01-01 CN claimed
WO-2018200412-A1 MEMBRANE ACTIVE MOLECULES BraneQuest, Inc. (US) 2018-11-01 WO claimed
US-20090082415-A1 Topical treatment of cataracts in dogs BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA 2009-03-26 US claimed
US-20080261317-A1 Methods of Detecting Myocardial Ischemia and Myocardial Infarction THE GENERAL HOSPITAL CORPORATION 2008-10-23 US claimed
WO-2006036476-A2 METHODS OF DETECTING MYOCARDIAL ISCHEMIA AND MYOCARDIAL INFARCTION THE GENERAL HOSPITAL CORPORATION (US) 2006-04-06 WO claimed
EP-0711774-B1 Crystalline cephem-addition salts and process for their preparation AVENTIS PHARMA GMBH (DE) 2002-02-13 EP claimed
US-5747484-A BACTERICIDES HOECHST AKTIENGESELLSCHAFT (DE) 1998-05-05 US claimed
EP-0428080-A2 Detection of appendicitis by measurement of ortho-hydroxyhippuric acid APPENDITECH INC. (US) 1991-05-22 EP claimed
CN-1006794-B PROCESS FOR THE PREPARATION OF ASYMMETRIC HYDANTOINS PFIZER (US) 1990-02-14 CN claimed
EP-0172719-B1 PROCESS FOR THE PRODUCTION AS ASYMMETRIC HYDANTOINS PFIZER INC. (US) 1988-09-21 EP claimed
CN-85105869-A The preparation method of asymmetric glycolylurea 1987-01-28 CN claimed
EP-0172719-A1 Process for the production as asymmetric hydantoins PFIZER INC. (US) 1986-02-26 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082415-A1 Topical treatment of cataracts in dogs AKR1A1, AKR1B1, AKR1C1 SLC1A2 2693/4885HDAC3 766/4885CA12 2986/4885
US-20200375958-A1 MEMBRANE ACTIVE MOLECULES GABRP, GRIN3A, GRIN2A SLC1A2 34/4885HDAC3 922/4885CA12 1212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.